CND Life Sciences, a medical technology company based in Scottsdale, Arizona, United States has announced the completion of a $4.5 million Seed financing round. The financing was led by Top Corner Capital.

CND Life Sciences is committed to assisting in the treatment of patients with neurodegenerative diseases and other conditions. CND launched the Syn-One Test®, the first commercially available test to detect, visualize, and quantify the presence of misfolded phosphorylated alpha-synuclein in cutaneous nerve fibers, from its CLIA-certified laboratory in Scottsdale, Arizona. The test is used as an objective diagnostic tool to help confirm synucleinopathy in patients with Parkinson's disease (PD), dementia with Lewy bodies (DLB), multiple system atrophy (MSA), or pure autonomic failure (PAF).

According to CND Life Sciences CEO Rick Morello, the funds will be used to accelerate the commercialization of Syn-One, which has nearly 700 neurologist clinician customers in over 40 states, as well as collaborations with biopharmaceutical companies.